• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Transforming growth factor beta (TGF-β) in adolescent chronic fatigue syndrome

hixxy

Senior Member
Messages
1,229
Location
Australia
J Transl Med. 2017 Dec 4;15(1):245. doi: 10.1186/s12967-017-1350-1.

Transforming growth factor beta (TGF-β) in adolescent chronic fatigue syndrome.

Wyller VB, Nguyen CB, Ludviksen JA, Mollnes TE.

Abstract

BACKGROUND:
Chronic fatigue syndrome (CFS) is a prevalent and disabling condition among adolescent. The disease mechanisms are unknown. Previous studies have suggested elevated plasma levels of several cytokines, but a recent meta-analysis of 38 articles found that of 77 different cytokines measured in plasma, transforming growth factor beta (TGF-β) was the only one that was elevated in patients compared to controls in a sufficient number of articles. In the present study we therefore compared the plasma levels of the three TGF-β isoforms in adolescent CFS patients and healthy controls. In addition, the study explored associations between TGF-β levels, neuroendocrine markers, clinical markers and differentially expressed genes within the CFS group.

METHODS:
CFS patients aged 12-18 years (n = 120) were recruited nation-wide to a single referral center as part of the NorCAPITAL project (ClinicalTrials ID: NCT01040429). A broad case definition of CFS was applied, requiring 3 months of unexplained, disabling chronic/relapsing fatigue of new onset, whereas no accompanying symptoms were necessary. Healthy controls (n = 68) were recruited from local schools. The three isoforms of TGF-β (TGF-β1, TGF-β2, TGF-β3) were assayed using multiplex technology. Neuroendocrine markers encompassed plasma and urine levels of catecholamines and cortisol, as well as heart rate variability indices. Clinical markers consisted of questionnaire scores for symptoms of post-exertional malaise, inflammation, fatigue, depression and trait anxiety, as well as activity recordings. Whole blood gene expression was assessed by RNA sequencing in a subgroup of patients (n = 29) and controls (n = 18).

RESULTS:
Plasma levels of all three isoforms of TGF-β were equal in the CFS patients and the healthy controls. Subgrouping according to the Fukuda and Canada 2003 criteria of CFS did not reveal differential results. Within the CFS group, all isoforms of TGF-β were associated with plasma cortisol, urine norepinephrine and urine epinephrine, and this association pattern was related to fatigue score. Also, TGF-β3 was related to expression of the B cell annotated genes TNFRSF13C and CXCR5.

CONCLUSIONS:
Plasma levels of all TGF-β isoforms were not altered in adolescent CFS. However, the TGF-β isoforms were associated with neuroendocrine markers, an association related to fatigue score. Furthermore, TGF-β3 might partly mediate an association between plasma cortisol and B cell gene expression. Trial registration Clinical Trials NCT01040429.

KEYWORDS:
Adolescent; Chronic fatigue syndrome; Inflammation; Transforming growth factor beta

https://www.ncbi.nlm.nih.gov/pubmed/29202780
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-017-1350-1
 

Gijs

Senior Member
Messages
691
So Montoya is wrong (?). TGF b must be replicated in adults too, but i think TGF B and cytokines are not usefull for markers in ME patiënts at all!
 

Londinium

Senior Member
Messages
178
So Montoya is wrong (?). TGF b must be replicated in adults too, but i think TGF B and cytokines are not usefull for markers in ME patiënts at all!

Given the selection criteria, I'm not sure there's much we can conclude from this study at all.
 

Murph

:)
Messages
1,799
Given the selection criteria, I'm not sure there's much we can conclude from this study at all.
I thought that when I started reading it, but they subgrouped for Canadian criteria and still came up empty.

>Subgrouping according to the Fukuda and Canada 2003 criteria of CFS did not reveal differential results.
 
Messages
80
Are plasma levels the most relevant thing to look at here? I vaguely remember Prof Edwards commenting that tgf-b is used to somehow mark cells for a longer period of time (if I understood correctly), so depending on how this stuff works (I have no clue obviously), maybe there are bouts of transiently high levels followed by a regression to the mean which would be difficult to capture unless it is known when to look as well as where? Or the plasma tgf-b is used up at roughly the same speed as it is produced so levels stay constant, but turnover may be higher if more cells are 'painted' with it?

It is interesting anyway that cortisol & (nor-)epinephrine are mentioned in this context since those do come up time and again.